New robot takes on chest cancer surgery in hong kong trial

NCT ID NCT06669104

Recruiting now Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new robotic system called Medtronic Hugo™ for surgery on chest cancers. It will enroll 50 adults who need robotic surgery for tumors in the chest or lung. The goal is to see if the robot is safe and effective by measuring how often surgeons need to switch to another method and how many complications occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Medtronic Hugo™ surgical robotic system
What this could lead to: If successful, this could show that the Hugo™ robot is a safe and effective option for robotic thoracic surgery, potentially expanding access to minimally invasive procedures.
What could go wrong: This is a small, early-stage study with only 50 participants, so results may not apply broadly. The robot is new and technical issues or complications could arise during surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THORACIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm thoracic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THORACIC CANCER

Contacts and locations

Locations

Prince of Wales Hospital
RECRUITING

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.